Skip to main content

CTOS 2023 Main banner

Schedule at a Glance

Icon Legend

This session is not in your schedule.

This session is in your schedule. Click again to remove it.

Back

Camelia Gliser, n/a

Servier Pharmaceuticals

Poster(s):

(P 66) PHASE I STUDY OF THE MUTANT IDH1 INHIBITOR IVOSIDENIB: LONG-TERM SAFETY AND CLINICAL ACTIVITY IN PATIENTS WITH CONVENTIONAL CHONDROSARCOMA